NASDAQ:ACON

Aclarion Q2 2024 Earnings Report

Aclarion logo
$2.85 +0.14 (+5.17%)
Closing price 06/26/2026 04:00 PM Eastern
Extended Trading
$2.76 -0.09 (-3.16%)
As of 06/26/2026 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aclarion EPS Results

Actual EPS
-$1,356.75
Consensus EPS
-$1,718.55
Beat/Miss
Beat by +$361.80
One Year Ago EPS
N/A

Aclarion Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aclarion Announcement Details

Quarter
Q2 2024
Time
During Market Hours
Conference Call Date
Tuesday, August 13, 2024
Conference Call Time
6:00PM ET

Upcoming Earnings

Aclarion's Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Aclarion Earnings Headlines

Aclarion (NASDAQ:ACON) Stock Rating Upgraded by Wall Street Zen
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
Aclarion Comments on Echo Lake News
See More Aclarion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aclarion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclarion and other key companies, straight to your email.

About Aclarion

Aclarion (NASDAQ:ACON), a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

View Aclarion Profile